[3–5] The functional role of ANRIL in cardiovascular disease has also been investigated in vascular smooth muscle, where ANRIL knockdown altered the expression of genes involved in the remodelling of the extracellular matrix, suggesting that ANRIL impacts on CHD risk via the modulation of these processes [6], leading to altered vascular structure and function. This evidence concerns the gene CDKN2B-AS1 and coronary artery disorder.